

Nicotinamide-based Compounds as Potent Inhibitors of Translational- and Transcriptional-related Kinases

Orally bioavailable compounds targeting two oncogenic proteins (MNK1/2 and p70S6K) with a single molecule show potent efficacy against multiple solid tumor cell lines, including breast, ovarian, lung, and colon cancers.

Researchers at Purdue University have designed molecules to concurrently inhibit two proteins important in tumorigenesis, MNK1/2 and p70S6K. Pharmaceutical companies have pursued MNK1/2 and p70S6K as individual targets; however, drugs targeting these proteins performed poorly as monotherapies. By inhibiting both MNK1/2 and p70S6K with a single molecule, the Purdue researchers' orally bioavailable compounds potently inhibit several solid tumor cancer cell lines, including breast, ovarian, lung, and colon cancer cells.

Technology Validation: At 200 nM, one of the drugs designed by the researchers completely inhibited the growth of Caki-1 (renal cancer) and MDA-MB-231 (breast cancer) cells. Compounds were tested against the NCI-60 cell line panel.

Advantages

- Targets two oncogenic proteins with a single molecule
- Effective against multiple solid tumor cell lines
- Orally bioavailable

Applications

- Anticancer drugs

Publication:

<https://www.sciencedirect.com/science/article/pii/S0045206825001786>

Technology ID

2022-SINT-69726

Category

Pharmaceuticals/Drug Discovery
& Development

Pharmaceuticals/Small Molecule
Therapeutics

Pharmaceuticals/Drug Delivery &
Formulations

Authors

Neetu Dayal

Herman O Sintim

Further information

Joe Kasper

JKasper@prf.org

Nathan Smith

nesmith@prf.org

View online



TRL: 3

Intellectual Property:

Provisional-Patent, 2022-04-06, United States | NATL-Patent, 2023-04-06, Japan | NATL-Patent, 2023-04-06, China | NATL-Patent, 2023-04-06, Canada | NATL-Patent, 2023-04-06, Europe | PCT-Patent, 2023-04-06, WO | NATL-Patent, 2024-10-04, United States

Keywords: MNK1/2 inhibitor, p70S6K inhibitor, dual protein inhibitor, anticancer drug, solid tumor cell lines, orally bioavailable compound, breast cancer cells, ovarian cancer cells, lung cancer cells, colon cancer cells